R1 RCM Inc. (NASDAQ:RCM) Receives Consensus Recommendation of “Hold” from Analysts

Shares of R1 RCM Inc. (NASDAQ:RCM) have earned a consensus rating of “Hold” from the eighteen analysts that are covering the company, Marketbeat Ratings reports. Thirteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $15.41.

Several equities analysts have weighed in on the company. Stephens downgraded R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Truist Financial decreased their price target on shares of R1 RCM from $16.00 to $14.30 and set a “hold” rating for the company in a research report on Thursday, August 8th. Leerink Partnrs lowered R1 RCM from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Cantor Fitzgerald restated a “neutral” rating and set a $14.30 price target on shares of R1 RCM in a report on Friday, October 4th. Finally, TD Cowen reiterated a “hold” rating and issued a $14.30 price objective (down previously from $20.00) on shares of R1 RCM in a research note on Monday, August 5th.

Institutional Investors Weigh In On R1 RCM

Several large investors have recently modified their holdings of the company. Advisors Asset Management Inc. acquired a new position in R1 RCM in the 1st quarter valued at $27,000. GAMMA Investing LLC raised its holdings in R1 RCM by 41.3% during the third quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock worth $37,000 after purchasing an additional 759 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in R1 RCM by 589.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider’s stock valued at $44,000 after purchasing an additional 2,669 shares during the period. Values First Advisors Inc. acquired a new stake in R1 RCM in the third quarter valued at about $88,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in R1 RCM in the 2nd quarter valued at approximately $86,000. 61.10% of the stock is owned by institutional investors and hedge funds.

R1 RCM Price Performance

R1 RCM stock opened at $14.31 on Thursday. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.76. The company has a 50-day moving average price of $14.22 and a 200 day moving average price of $13.44. R1 RCM has a 12-month low of $8.87 and a 12-month high of $15.12. The stock has a market cap of $6.04 billion, a P/E ratio of -95.40 and a beta of 0.84.

R1 RCM (NASDAQ:RCM) last announced its quarterly earnings results on Tuesday, November 5th. The healthcare provider reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The business had revenue of $656.80 million during the quarter, compared to analyst estimates of $640.93 million. R1 RCM had a negative net margin of 2.48% and a negative return on equity of 2.18%. The firm’s revenue was up 14.7% on a year-over-year basis. Sell-side analysts anticipate that R1 RCM will post -0.38 earnings per share for the current year.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.